NCT02299518 - Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 18, 2015

Primary Completion Date

March 6, 2018

Study Completion Date

March 6, 2018

Conditions

Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid Leukemia

Interventions

DRUG

mitoxantrone hydrochloride

Given IV

DRUG

etoposide

Given IV and PO

DRUG

cytarabine

Given IV

DRUG

selinexor

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

43210

The State Ohio University Comprehensive Cancer Center, Columbus